December 2, 2016 07:10 AM EST
Startups
R&D

Cut­ting back in the UK, Take­da spins out its top neu­ro­science team in­to a transat­lantic biotech

John Carroll

Editor & Founder

As Take­da con­tin­ues a glob­al R&D over­haul that in­cludes a wind down of UK op­er­a­tions, the Japan­ese phar­ma com­pa­ny is spin­ning out its neu­ro­science team …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Re­cur­sion re­duces work­force; Ox­ford Nanopore teams up with UK Biobank

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

A service from the Financial Times